Mantle Cell Lymphoma

Martin Dreyling, MD, discusses the next steps for research with ibrutinib in the mantle cell lymphoma space following the presentation of data from the phase 3 TRIANGLE study.

Mixed study results for ibrutinib have led the developer to voluntarily withdraw the agent from the United States market for the treatment of mantle cell and marginal zone lymphoma subgroups.

Mitchell Smith, MD, PhD, discusses how the updated results of the phase 2 ECOG-ACRIN E1411 trial of patients with previously untreated mantle cell lymphoma can be interpreted in context of data supporting the use of the Bruton’s tyrosine kinase inhibitor ibrutinib in this setting.

Clinical trials exploring regimens without ASCT consolidation in young patients with MCL are needed, and maintenance with rituximab should be considered for patients after first-line treatment with bendamustine plus rituximab and R-CHOP

Lori Leslie, MD, describes the cohorts of the phase 2 ZUMA-2 study and discusses the potential impact of brexucabtagene autoleucel in the mantle cell lymphoma landscape.

Mitchell Smith, MD, PhD, discusses the updated results of the phase 2 ECOG-ACRIN E1411 trial of patients with previously untreated mantle cell lymphoma.

A 90-day complete response rate of 92% was observed with bispecific CAR T-cell therapy for patients with relapsed/refractory mantle cell lymphoma.

Patients treated with brexucabtagene autoleucel as standard of care in US Lymphoma CAR T Consortium centers responded to treatment consistently with the ZUMA-2 trial, showing real-world efficacy and safety as well as additional data on outcomes for patients with high-risk features and different bridging therapies.

The FDA has approved the first non-covalent Bruton tyrosine kinase inhibitor for the treatment of relapsed or refractory mantle cell lymphoma in adult patients, based on clinical studies conducted with participation by Florida Cancer Specialists & Research Institute.

Recent findings that stratify the use of Bruton tyrosine kinase inhibitors in combination with autologous stem cell transplant were explored during major medical conferences in 2022.

Brian Hill, MD, discusses the use of CAR T-cell therapy in earlier lines of treatment for mantle cell lymphoma and identifies other novel agents in this setting.

Yazan Samhouri, MD, discusses his impressions of the TRIANGLE clinical trial presented at the 2022 American Society of Hematology Annual Meeting.

Based on findings from the phase 1/2 BRUIN trial, pirtobrutinib has been approved by the FDA for patients with relapsed/refractory mantle cell lymphoma.

Martin Dreyling, MD, discusses the outcomes of the phase 3 TRIANGLE study evaluating ibrutinib in patients with mantle cell lymphoma.

In an interview with Targeted Oncology, Martin Dreyling, MD, discussed the implications of the findings from the TRIANGLE study in patients with mantle cell lymphoma.

Martin Dreyling, MD, discusses findings from the phase 3 TRIANGLE study of ibrutinib in patients with mantle cell lymphoma.

Phase 3 TRIANGLE results show the efficacy of ibrutinib induction and ibrutinib maintenance in patients with mantle cell lymphoma.

A phase 1/2 trial has revealed the promise of using zilovertamab plus ibrutinib for the treatment of mantle cell lymphoma and chronic lymphocytic leukemia.

Pretreatment with Obinutuzumab aids fixed-duration regimen of glofitamab in high complete responses among a group of heavily pretreated patients with relapsed or refractory mantle cell lymphoma.

Tycel Phillips, MD, discusses recent changes in the mantle cell lymphoma treatment landscape.

In an interview with Targeted Oncology, Jia Ruan, MD, PhD, discussed the updates in the mantle cell lymphoma space, including understanding molecular pathogenesis and risk stratification for this patient population.

An analysis of data from 2002-2015 shows that for patients with mantle cell lymphoma achieving event-free survival after two years may be a prognostic factor for better overall survival outcomes.

An investigational agent is planned for a phase 1 trial of patients with mantle cell lymphoma after preclinical data showed antitumor activity.

Cyrus M. Kahn, MD, discusses the evolution of the treatment landscape for patients with mantle cell lymphoma.

In an interview with Targeted Oncology, Tycel Phillips, MD, discussed the many treatment options available and those that are being examined for patients with mantle cell lymphoma in the second-line setting.

At the 2022 NCCN annual congress, Tycel Phillips, MD, discussed different strategies that can be effective as second-line treatments in various patients who have relapsed/refractory mantle cell lymphoma.

There have been marked improvements in expected remission and overall survival rates in mantle cell lymphoma even though a cure for this disease remains elusive.

Traditionally, MCL was dichotomized based on the age of the patient and their ability to tolerate intensive therapy, [but] now we have to take into consideration biological differences across patients that go well beyond age, says Andre H. Goy, MD.

Christopher J. Melani, MD, discusses the combination investigated in the ViPOR study of patients with relapsed/refractory or untreated mantle cell lymphoma.